Security key
00461U105
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q3 2020 13F Holders as of 30 Sep 2020
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Total 13F shares
- 25,553,008
- Total 13F value
- $65,673,000
- Share change
- -2,893,420
- SEC-reported price per share
- $2.57
- Number of holders
- 52
- Value change
- -$3,889,513
- Number of buys
- 16
- Number of sells
- 28
- Shares outstanding
- 138,752,791
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2020
Institutions
52
Top holders
10
ACRS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00461U105
Recent filing periods:
Ownership snapshot
Top reported holders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MFN Partners Management, LP
Disclosed value leader
MFN Partners Management, LP
Comparable rows
15/15
Latest evidence
30 Jun 2020
13F
Lead comparable stake: 2.4%
Showing 1-6 of 15 holder rows.
Quick read
MFN Partners Management, LP leads the comparable SEC ownership view at 2.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MFN Partners Management, LP's linked filing trail.
Comparable ownership
Top 5
MFN Partners Management, LP
2.4%
RENAISSANCE TECHNOLOGIES LLC
2.4%
Samsara BioCapital, LLC
1.9%
ADAGE CAPITAL PARTNERS GP, L.L.C.
1.8%
Sofinnova Investments, Inc.
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MFN Partners Management, LP |
13F
Company
|
2.4%
|
$5,409,000
3,338,718 shares
|
— | 30 Jun 2020 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
2.4%
|
$5,313,000
3,279,840 shares
|
— | 30 Jun 2020 |
| Samsara BioCapital, LLC |
13F
Company
|
1.9%
|
$4,225,000
2,608,117 shares
|
— | 30 Jun 2020 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
1.8%
|
$4,050,000
2,500,000 shares
|
— | 30 Jun 2020 |
| Sofinnova Investments, Inc. |
13F
Company
|
1.4%
|
$3,097,000
1,911,573 shares
|
— | 30 Jun 2020 |
| Endurant Capital Management LP |
13F
Company
|
1.2%
|
$2,801,000
1,728,787 shares
|
— | 30 Jun 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
52
Shares
25,553,008
Rows available
52
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2020 vs Q3 2025 Across Filers
Q3 2025 holders
103
Q3 2020 holders
52
Holder diff
-51
| Investor | Q3 2025 Shares | Q3 2020 Shares | Share Diff | Share Chg % | Q3 2025 value | Q3 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend